Observational case series on a group of psoriasis patients who failed to respond to any TNF blockers.
Fiche publication
Date publication
février 2014
Auteurs
Membres identifiés du Cancéropôle Est :
Pr AUBIN François
Tous les auteurs :
Viguier M, Livideanu C, Beylot-Barry M, Richard MA, Paul C, Bachelez H, Aubin F
Lien Pubmed
Résumé
INTRODUCTION: Data that can identify the patients who will not respond to anti-TNF agents are sparse. Therefore, the authors wished to describe specific clinical factors that could be associated with a non-response to any available TNF blockers in patients with psoriasis. METHODS: A retrospective observational study was performed through the mailing of a questionnaire to five departments of Dermatology. Only psoriasis patients who were not responsive to all available anti-TNF agents (etanercept, infliximab and adalimumab), whatever the chronology of their use, were included. RESULTS: Twenty-two patients were included. Forty patients (64%) did not work at the time of the study and 12 (55%) qualified for Social Security Disability Allowance. Forty patients (64%) were considered as "overweight". Fifty-nine percent of patients were smokers. Antinuclear antibodies were positive in 9 out of 16 patients tested (56%) at the time of non-response. Ustekinumab, which was further introduced in 19 patients, led to PASI 75 in all (94%) but one patient. CONCLUSION: The data identified different clinical factors associated with a non-response to any available TNF blockers. Furthermore, non-responder patients were highly responsive to ustekinumab suggesting that in few psoriasis patients, TNF blockade is not the best target and other TNF-independent signaling pathway should be considered.
Référence
J Dermatolog Treat. 2014 Feb;25(1):75-7